Pfizer Inc. (NYSE:PFE) Shares Purchased by Hengehold Capital Management LLC

Hengehold Capital Management LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 119,846 shares of the biopharmaceutical company’s stock after buying an additional 2,043 shares during the period. Hengehold Capital Management LLC’s holdings in Pfizer were worth $3,180,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Fred Alger Management LLC boosted its holdings in shares of Pfizer by 6.6% during the second quarter. Fred Alger Management LLC now owns 95,592 shares of the biopharmaceutical company’s stock worth $2,675,000 after purchasing an additional 5,932 shares during the last quarter. Caxton Associates LP purchased a new position in Pfizer during the second quarter worth about $738,000. AXA S.A. grew its holdings in Pfizer by 4.9% in the 2nd quarter. AXA S.A. now owns 2,632,380 shares of the biopharmaceutical company’s stock valued at $73,654,000 after buying an additional 123,605 shares during the period. AQR Capital Management LLC increased its stake in shares of Pfizer by 1.6% during the 2nd quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock valued at $17,068,000 after acquiring an additional 9,435 shares during the last quarter. Finally, Drucker Wealth 3.0 LLC purchased a new position in shares of Pfizer during the 2nd quarter worth about $2,782,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 1.7 %

PFE opened at $26.46 on Friday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $149.94 billion, a PE ratio of 35.75, a P/E/G ratio of 0.64 and a beta of 0.64. The firm’s fifty day moving average price is $26.07 and its 200 day moving average price is $27.96.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the prior year, the business posted ($0.17) EPS. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.50%. Pfizer’s payout ratio is 227.03%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on PFE. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Wolfe Research assumed coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Guggenheim cut their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Finally, Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $32.00.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.